Johns Hopkins ABX Guide
Ibrexafungerp
INDICATIONS
FDA
FDA
- Ibrexafungerp is indicated for the treatment of vulvovaginal candidiasis (VVC) in adults and post-menarchal pediatric females.
- On September 27, 2023, SCYNEXIS issued a voluntary recall of ibrexfungerp tablets due to cross-contamination with a non-antibacterial beta-lactam drug substance.
- At the time of this update, contamination concerns are still ongoing.
- A phase 3, randomized, double-blind study for patients with invasive candidiasis treated with an IV echinocandin followed by either ibrexafungerp or oral fluconazole (MARIO; NCT05178862) was suspended due to this contamination risk. It is unlikely this phase 3 study will re-open.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: May 10, 2024
Citation
Dzintars, Kathryn. "Ibrexafungerp." Johns Hopkins ABX Guide, The Johns Hopkins University, 2024. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp.
Dzintars K. Ibrexafungerp. Johns Hopkins ABX Guide. The Johns Hopkins University; 2024. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp. Accessed October 31, 2025.
Dzintars, K. (2024). Ibrexafungerp. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp
Dzintars K. Ibrexafungerp [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2024. [cited 2025 October 31]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ibrexafungerp
ID - 540761
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2024/05/10/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540761/all/Ibrexafungerp
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
